# A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly

Source: https://onco.cc/trials/nct05827016/  
OnCo record `nct05827016` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Iberdomide, Lenalidomide in multiple myeloma, run by Bristol-Myers Squibb, active and no longer recruiting.

## Summary

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma is a phase 3 interventional study registered as NCT05827016 by Bristol-Myers Squibb, with 1230 participants enrolled, started 2023-06-22 and due to reach its primary completion in 2029-03-15. Interventions recorded: Iberdomide, Lenalidomide. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05827016
- Phase: 3
- Setting: A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance)
- Sponsor: Bristol-Myers Squibb
- Enrolled: 1230

## Sources

- ClinicalTrials.gov NCT05827016: https://clinicaltrials.gov/study/NCT05827016

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Iberdomide](https://onco.cc/drugs/iberdomide/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct05827016.json